Target intelligence / Profile preview

MicroRNA 3613 (miR-3613 (or miR-3613-3p))

Target
miR-3613 (or miR-3613-3p)
Molecular classification
MicroRNA, Non-coding RNA, Other
01

Overview

MicroRNA 3613 is a small non-coding RNA molecule encoded by the MIR3613 gene, located near the RB1 and BRCA2 tumor suppressor loci on chromosome 13. As a microRNA, miR-3613-3p functions in post-transcriptional regulation of gene expression by binding to the 3' untranslated regions of target mRNAs, leading to their translational repression or degradation. It is downregulated or deleted in several cancers (notably breast cancer) and acts as a tumor suppressor by inhibiting cell proliferation, suppressing tumor growth and metastasis, and promoting apoptosis of cancer cells. Key direct targets include oncogenes and cell cycle regulators such as SMAD2 and EZH2. Restoration of miR-3613-3p sensitizes tumor cells to certain anti-cancer drugs (e.g., Palbociclib) and its altered levels are being explored both as diagnostic/prognostic biomarkers and as a therapeutic strategy in oncology.

Other names
hsa-mir-3613MIR3613microRNA-3613-3pmiR-3613-3p
02

Mechanism of action

Post-transcriptional inhibition of specific oncogene transcripts (notably SMAD2, EZH2, SMS, PAFAH1B2, PDK3). Enhancement of cell cycle arrest and apoptosis through suppression of target proteins.

03

Biological functions

Regulation of gene expressionPost-transcriptional gene silencingCell cycle controlApoptosisCell proliferationTumor suppression
04

Disease associations

Cancer (notably breast cancer, especially triple-negative and estrogen receptor-positive breast cancers)Cancer biomarkerOther (potential role in cardiovascular pathology)
05

Safety considerations

None specifically reported for direct targeting; as with other microRNA therapeutics, potential challenges include off-target effects and delivery
06

Interacting drugs

Palbociclib (sensitization effect noted when miR-3613-3p is overexpressed in cancer cells)
07

Biomarkers

Circulating miR-3613-3p levels (plasma or serum) as a biomarker for diagnosis/prognosis in breast cancer and lung adenocarcinomaMIR3613 genomic deletion status as a molecular marker for prognosis in ER+ breast cancer

Beyond the preview

Go deeper on MicroRNA 3613 (miR-3613 (or miR-3613-3p)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicroRNA 3613 (miR-3613 (or miR-3613-3p)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call